Table 1.

Overview of included study measures and scales in the TRACK-PD study

Method	Outcome	Scales	Visit 1 (Baseline)	Visit 2 (2 Years)˟	Visit 3 (4 Years)˟
Assessed by trial assessor	Motor functioning in ‘ON’ state	MDS-UPDRS III (including H&Y stage)	X*	X*	X*
		MDS-UPDRS IV	X*	X*	X*
	Neuropsychological symptoms	MoCA	X	X	X
		Phonemic and semantic fluency	X	X	X
		15 Words Test	X	X	X
		Benton Judgment of Line Orientation	X	X	X
		Letter Number Sequencing	X	X	X
		Symbol Digit Modalities Test	X	X	X
		MDS-UPDRS I	X*	X*	X*
	Demographics and lifestyle	Medical history	X	X	X
		Medication	X	X	X
	Biospecimen	EDTA Plasma (DNA)	X
		Pax Gene (RNA)	X
	Brain structure and function	Resting-state functional MRI	X	X	X
		Structural MRI (T1, T2*, neuromelanin, DWI)	X	X	X
Wearable sensors	Motor parameters	IMU including 3-axis accelerometer and 3-axis gyroscope	X	X	X
Self-reported patient questionnaires	Neuropsychiatric symptoms	BDI	X	X	X
		QUIP-RS	X	X	X
		PAS	X	X	X
	Quality of life	PDQ-8	X*	X*	X*
	Autonomic symptoms	SCOPA-AUT	X	X	X
	Sleep disorders	RBDQ	X	X	X
	Various	MDS-UPDRS II	X*	X*	X*

BDI Beck Depression Inventory, HC healthy controls, H&Y Hoehn and Yahr scale, IMU Inertial Measurement Unit, MDS-UPDRS Movement Disorders Society Unified Parkinson Disease Rating Scale, MoCA Montreal Cognitive Assessment, NPA Neuropsychological assessment, PAS Parkinson Anxiety Scale, PD Parkinson’s disease patients, PDQ-8 Parkinson’s Disease Questionnaire, QUIP-RS Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease, RBDSQ REM-sleep behaviour disorder screening questionnaire, SCOPA-AUT Scales for Outcomes in Parkinson’s Disease - Autonomic dysfunction questionnaire

˟ ± 60 days; * Only for PD patients